The immunotherapy, pembrolizumab, is active against mucosal … – EurekAlert (press release)
|
The immunotherapy, pembrolizumab, is active against mucosal …
EurekAlert (press release) Clinical trials of a new immunotherapy, pembrolizumab, have shown that it prolongs life significantly for patients with bladder cancer and is active against a rare … |
